Maravai LifeSciences (MRVI) Stock Price, News & Analysis $5.12 -0.06 (-1.16%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$5.02▼$5.1950-Day Range$4.70▼$9.8752-Week Range$4.52▼$16.90Volume1.42 million shsAverage Volume2.62 million shsMarket Capitalization$1.29 billionP/E Ratio28.44Dividend YieldN/APrice Target$13.90 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Maravai LifeSciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside171.5% Upside$13.90 Price TargetShort InterestHealthy6.68% of Float Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.10) to ($0.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.18 out of 5 starsMedical Sector353rd out of 933 stocksPharmaceutical Preparations Industry138th out of 429 stocks 3.3 Analyst's Opinion Consensus RatingMaravai LifeSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.90, Maravai LifeSciences has a forecasted upside of 171.5% from its current price of $5.12.Amount of Analyst CoverageMaravai LifeSciences has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.68% of the float of Maravai LifeSciences has been sold short.Short Interest Ratio / Days to CoverMaravai LifeSciences has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Maravai LifeSciences has recently decreased by 4.71%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMaravai LifeSciences does not currently pay a dividend.Dividend GrowthMaravai LifeSciences does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMaravai LifeSciences has received a 67.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Deoxyribonucleic acid (DNA)", "Microbiology laboratory services for research", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Maravai LifeSciences is -1.23. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Maravai LifeSciences this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for MRVI on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 40 people have added Maravai LifeSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -65% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Maravai LifeSciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.22% of the stock of Maravai LifeSciences is held by insiders.Percentage Held by Institutions50.25% of the stock of Maravai LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Maravai LifeSciences are expected to grow in the coming year, from ($0.10) to ($0.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Maravai LifeSciences is 28.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 109.35.Price to Earnings Ratio vs. SectorThe P/E ratio of Maravai LifeSciences is 28.44, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 104.39.Price to Book Value per Share RatioMaravai LifeSciences has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Maravai LifeSciences Stock (NASDAQ:MRVI)Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, Viral Clearance Prediction kits, and custom services. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.Read More MRVI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRVI Stock News HeadlinesDecember 8, 2023 | americanbankingnews.comMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives Average Rating of "Moderate Buy" from BrokeragesNovember 24, 2023 | finance.yahoo.comAre Options Traders Betting on a Big Move in Maravai LifeSciences (MRVI) Stock?December 10, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 16, 2023 | finance.yahoo.comAnalyst Forecasts Just Became More Bearish On Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)November 9, 2023 | benzinga.comMaravai LifeSciences Stock (NASDAQ:MRVI) Earnings Dates and Earning CallsNovember 9, 2023 | finance.yahoo.comMaravai LifeSciences Announces November 2023 Investor Conference ScheduleNovember 8, 2023 | msn.comMaravai hits 52-week low after Q3 miss, cost cuttingNovember 8, 2023 | finance.yahoo.comMaravai LifeSciences (MRVI) Q3 2023 Earnings Call TranscriptDecember 10, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 8, 2023 | seekingalpha.comMaravai LifeSciences Holdings, Inc. 2023 Q3 - Results - Earnings Call PresentationNovember 7, 2023 | benzinga.comMaravai LifeSciences: Q3 Earnings InsightsNovember 7, 2023 | finance.yahoo.comMaravai LifeSciences Holdings Inc (MRVI) Reports Q3 2023 Financial Results Amidst Market RealignmentNovember 2, 2023 | finance.yahoo.comTriLink BioTechnologies® Expands Capabilities with Launch of ‘Analytical Sciences Center of Excellence’October 28, 2023 | seekingalpha.comMaravai LifeSciences: Falling Victim To COVID Boom And BustOctober 17, 2023 | finance.yahoo.comMaravai LifeSciences To Host Earnings Conference Call on Tuesday, November 7, 2023September 29, 2023 | finance.yahoo.comMaravai LifeSciences Hosts 2023 Investor R&D DaySeptember 26, 2023 | finance.yahoo.comIs Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic ValueSeptember 5, 2023 | finance.yahoo.comMaravai LifeSciences to Host 2023 Investor R&D DayAugust 29, 2023 | markets.businessinsider.comRBC Capital Sticks to Its Buy Rating for Maravai Lifesciences Holdings (MRVI)August 23, 2023 | finance.yahoo.comCygnus Technologies Receives 2023 R&D 100 Award for MockV® RVLP KitAugust 22, 2023 | finance.yahoo.com11 Most Undervalued Biotech Stocks to Buy According to AnalystsAugust 9, 2023 | finance.yahoo.comMaravai LifeSciences Announces August 2023 Investor Conference ScheduleAugust 9, 2023 | finance.yahoo.comWhat Does The Future Hold For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)? These Analysts Have Been Cutting Their EstimatesAugust 8, 2023 | 247wallst.comKeyBanc Downgrades Maravai LifeSciencesAugust 8, 2023 | msn.comGoldman Sachs Maintains Maravai LifeSciences Holdings Inc - (MRVI) Neutral RecommendationAugust 8, 2023 | msn.comKeybanc Downgrades Maravai LifeSciences Holdings Inc - (MRVI)August 8, 2023 | msn.comMaravai LifeSciences Holdings Non-GAAP EPS of $0.00 misses by $0.01, revenue of $68.9M misses by $2.23MSee More Headlines Receive MRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/10/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRVI CUSIPN/A CIK1823239 Webwww.maravai.com Phone858-546-0004FaxN/AEmployees670Year FoundedN/APrice Target and Rating Average Stock Price Target$13.90 High Stock Price Target$24.00 Low Stock Price Target$7.00 Potential Upside/Downside+171.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$0.18 Trailing P/E Ratio28.44 Forward P/E RatioN/A P/E GrowthN/ANet Income$220.21 million Net Margins5.86% Pretax Margin13.69% Return on Equity9.38% Return on Assets3.70% Debt Debt-to-Equity Ratio0.62 Current Ratio8.96 Quick Ratio8.33 Sales & Book Value Annual Sales$419.52 million Price / Sales3.07 Cash Flow$1.94 per share Price / Cash Flow2.64 Book Value$3.55 per share Price / Book1.44Miscellaneous Outstanding Shares251,283,000Free Float250,730,000Market Cap$1.29 billion OptionableNot Optionable Beta-0.31 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Carl W. Hull (Age 64)Co-Founder & Executive Chairman Comp: $1.45MMr. William E. Martin III (Age 48)Chief Executive Officer Comp: $2.07MMr. Kevin M. Herde (Age 51)Executive VP & CFO Comp: $778.28kDr. Peter Michael Leddy Ph.D. (Age 60)Executive VP & Chief Administrative Officer Comp: $757kMs. Christine Dolan (Age 55)Executive Vice President of Biologics Safety Testing Comp: $755.97kMs. Debra HartSenior Director of Investor RelationsMr. Kurt Oreshack (Age 42)Executive VP, General Counsel & Secretary Comp: $701.4kMs. Becky BuzzeoExecutive VP & Chief Commercial OfficerDr. Kate E. Broderick Ph.D.Chief Innovation OfficerMr. Christopher BenoitExecutive Vice President of EnzymesMore ExecutivesKey CompetitorsAbCellera BiologicsNASDAQ:ABCLPacira BioSciencesNASDAQ:PCRXArvinasNASDAQ:ARVNAurinia PharmaceuticalsNASDAQ:AUPHAgios PharmaceuticalsNASDAQ:AGIOView All CompetitorsInstitutional OwnershipHudson Bay Capital Management LPBought 416,876 shares on 12/7/2023Ownership: 0.262%Citigroup Inc.Sold 2,159,294 shares on 12/6/2023Ownership: 0.072%American Century Companies Inc.Bought 32,869 shares on 11/30/2023Ownership: 0.024%Deutsche Bank AGSold 1,434,756 shares on 11/24/2023Ownership: 0.010%Public Employees Retirement System of OhioSold 4,957 shares on 11/16/2023Ownership: 0.018%View All Institutional Transactions MRVI Stock Analysis - Frequently Asked Questions Should I buy or sell Maravai LifeSciences stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MRVI shares. View MRVI analyst ratings or view top-rated stocks. What is Maravai LifeSciences' stock price target for 2024? 8 analysts have issued 1-year price objectives for Maravai LifeSciences' shares. Their MRVI share price targets range from $7.00 to $24.00. On average, they anticipate the company's share price to reach $13.90 in the next twelve months. This suggests a possible upside of 171.5% from the stock's current price. View analysts price targets for MRVI or view top-rated stocks among Wall Street analysts. How have MRVI shares performed in 2023? Maravai LifeSciences' stock was trading at $14.31 at the start of the year. Since then, MRVI shares have decreased by 64.2% and is now trading at $5.12. View the best growth stocks for 2023 here. When is Maravai LifeSciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024. View our MRVI earnings forecast. How were Maravai LifeSciences' earnings last quarter? Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) posted its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.01. The business earned $66.87 million during the quarter, compared to the consensus estimate of $75.23 million. Maravai LifeSciences had a net margin of 5.86% and a trailing twelve-month return on equity of 9.38%. What ETFs hold Maravai LifeSciences' stock? ETFs with the largest weight of Maravai LifeSciences (NASDAQ:MRVI) stock in their portfolio include Morningstar US Small Growth (MSGR), Janus Henderson Small Cap Growth Alpha ETF (JSML), First Trust Health Care AlphaDEX Fund (FXH) and Putnam BioRevolution ETF (SYNB).WisdomTree U.S. SmallCap Fund (EES). What guidance has Maravai LifeSciences issued on next quarter's earnings? Maravai LifeSciences updated its FY23 earnings guidance on Tuesday, November, 7th. The company provided earnings per share (EPS) guidance of ($0.01) - $0.01 for the period, compared to the consensus EPS estimate of $0.06. The company issued revenue guidance of $275-285 million, compared to the consensus revenue estimate of $308.70 million. When did Maravai LifeSciences IPO? (MRVI) raised $1.3 billion in an initial public offering on Friday, November 20th 2020. The company issued 50,000,000 shares at a price of $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs served as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers. Who are Maravai LifeSciences' major shareholders? Maravai LifeSciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (3.25%), 12 West Capital Management LP (2.57%), Mackenzie Financial Corp (1.96%), Braidwell LP (1.58%), Clearbridge Investments LLC (1.23%) and Jennison Associates LLC (1.01%). How do I buy shares of Maravai LifeSciences? Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:MRVI) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.